CERo Preclinical Data Shows CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.  The data were presented in a poster at the Society for Immunology of Cancer (SITC) 2024 conference held in Houston November 6-10, 2024.

https://www.globenewswire.com/news-release/2024/11/11/2978290/0/en/CERo-Therapeutics-Inc-Presents-Preclinical-Data-Demonstrating-CER-1236-Killing-Ovarian-Cancer-Cell-Lines-Without-Toxicity.html